GlassScriptPhysician profile
Jaime Jane Vanourny
NPI 1508028093
$13,166.34
in general payments reported to CMS, 2019-2025
36 companies · $2,032 in 2025
The $2,032 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,176 · 2020: $401 · 2021: $1,000 · 2022: $1,534 · 2023: $1,722 · 2024: $5,301 · 2025: $2,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,327 · Consulting Fee: $2,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,327.38 |
| Consulting Fee | $2,727.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,585.86 | 2020-2025 | Tremfya |
| Abbvie INC. | $2,291.23 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Ucb, INC. | $880.71 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $623.87 | 2019-2024 | |
| Lilly USA, LLC | $619.00 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $615.04 | 2019-2025 | Nemluvio, Epsolay, Oracea |
| Sun Pharmaceutical Industries INC. | $585.51 | 2020-2025 | Ilumya, Odomzo, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $547.59 | 2022-2025 | Sotyktu |
| Pfizer INC. | $528.88 | 2019-2025 | |
| Incyte Corporation | $461.39 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $442.43 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $420.78 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $338.71 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.90 | 2022-2025 | Spevigo |
| Merz North America, INC. | $162.40 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $159.48 | 2021-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $107.52 | 2023-2024 | Vtama |
| Fresenius Kabi USA, LLC | $80.12 | 2024 | Idacio |
| Genentech USA, INC. | $65.47 | 2019 | |
| Organon LLC | $58.63 | 2024-2025 | Vtama |
| Allergan, INC. | $44.74 | 2022 | |
| Almirall LLC | $41.43 | 2022-2023 | Klisyri |
| Sandoz INC. | $39.23 | 2023-2024 | Hyrimoz |
| Mentor Worldwide LLC | $38.25 | 2020 | |
| Epi Health, LLC | $27.92 | 2020 | |
| Mayne Pharma Commercial LLC | $26.15 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.78 | 2023 | Jublia |
| Celgene Corporation | $22.25 | 2019 | |
| Journey Medical Corporation | $18.36 | 2021 | |
| Strata Skin Sciences, INC. | $17.66 | 2021 | |
| Vyne Pharmaceuticals INC. | $15.13 | 2021 | |
| Arcutis Biotherapeutics, INC. | $14.81 | 2023 | |
| Botanix Sb INC | $13.89 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $13.10 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $11.12 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Vanourny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.